E-ISSN 2534-9821
 
2023, Vol: 7, Issue: 11
7 / 11Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Case Report
Online Published: 04 Nov 2019
 


Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description

Endri Mauro, Filippo Gherlinzoni.


Cited By: 1

Abstract
Background Paroxysmal Nocturnal Hemoglobinuria (PNH) pathogenesis is due to acquired lack of glycosylphosphatidylinositol-anchored protein complement regulatory proteins (CD55 and CD59) and intra-extravascular hemolysis. Eculizumab is a monoclonal antibody binding complement protein 5 (C5 receptor CD59), blocking complement upstream and reducing hemolysis. Case Summary In 1999 we diagnosed PNH in a male 54 year-old. Therapy with prednisone and blood transfusions started. After 13 years (2012) of continuative steroid, we started eculizumab every 14 days. Clinical and laboratory improvement has been reported, the prednisone therapy has been tapered; no further hemolytic crises reappeared. However, mild anemia, high reticulocytes count, high LDH serum levels are still reported. Actually, despite to suboptimal response, the patient shows a good quality of life. Conclusion Here we report a case of PNH with a fully documented medical history of long-term steroid therapy confirming efficacy and safety of eculizumab. However “C3 tick over” effect may induce suboptimal clinical results with residual hemolytic activity also on heavy steroid treated patients.

Key words: paroxysmal nocturnal hemoglobinuria, eculizumab, steroids, hemolysis


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Endri Mauro
Articles by Filippo Gherlinzoni
on Google
on Google Scholar


This Article Cited By the following articles

GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets
Front. Oncol. 2020; 10(): .

1
 
How to Cite this Article
Pubmed Style

Mauro E, Gherlinzoni F, . Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. Int J Med Rev Case Rep. 2019; 3(11): 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria

Web Style

Mauro E, Gherlinzoni F, . Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. https://www.mdpub.net/?mno=63629 [Access: October 13, 2024]. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria

AMA (American Medical Association) Style

Mauro E, Gherlinzoni F, . Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. Int J Med Rev Case Rep. 2019; 3(11): 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


Vancouver/ICMJE Style

Mauro E, Gherlinzoni F, . Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. Int J Med Rev Case Rep. (2019), [cited October 13, 2024]; 3(11): 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


Harvard Style

Mauro, E. ., Gherlinzoni, F. & (2019) Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. Int J Med Rev Case Rep, 3 (11), 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


Turabian Style

Mauro, Endri , Filippo Gherlinzoni, and . 2019. Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. International Journal of Medical Reviews and Case Reports, 3 (11), 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


Chicago Style

Mauro, Endri , Filippo Gherlinzoni, and . "Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description." International Journal of Medical Reviews and Case Reports 3 (2019), 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


MLA (The Modern Language Association) Style

Mauro, Endri , Filippo Gherlinzoni, and . "Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description." International Journal of Medical Reviews and Case Reports 3.11 (2019), 773-776. Print. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


APA (American Psychological Association) Style

Mauro, E. ., Gherlinzoni, F. & (2019) Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description. International Journal of Medical Reviews and Case Reports, 3 (11), 773-776. doi:10.5455/IJMRCR.Eculizumab-Paroxysmal-Nocturnal-Hemoglobinuria


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports  (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500